Corbus Pharmaceuticals Holdings, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $113.5M
- Price
- $5.85
- % Change (Daily % change from the live per-ticker quote feed.)
- -4.57%
- Volume
- 793.5K
About
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.
Quick stats
Shares outstanding19.4M
Computed float17.0M
Float / shares87.4%
Cash runway (months)11.7
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001595097
Websitehttps://www.corbuspharma.com
AI Summary
AI-generated1/18
standardbullishclinical trial
Corbus Pharmaceuticals Announces First Patient Dosed in TEMPO-1 Registrational Study of CRB-701 in Patients with 2L+ Oropharyngeal Cancer
Corbus Pharmaceuticals dosed the first patient in TEMPO-1, a registrational study of its Nectin-4-targeted ADC CRB-701 in 2L+ oropharyngeal squamous cell carcinoma.
The randomized 250-patient trial uses ORR as the primary endpoint intended to support accelerated approval, with overall survival backing a potential conversion to full approval.
The FDA cleared the study design based on Phase 1/2 data showing a 42.9% confirmed ORR, 6.3-month median DoR, and 5.6-month median PFS (ongoing) at the 3.6 mg/kg dose.
Roughly 14,000 U.S. OPSCC patients annually are eligible for 2L treatment, a population management says has seen little standard-of-care change since PD-1 inhibitors.
Red flags
- early milestone; readout likely far out and Phase 1/2 ORR may not replicate in the larger controlled trial